ATC
SMMT icon

Adirondack Trust Company’s Summit Therapeutics SMMT Stock Holding History

Adirondack Trust Company’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.4K Hold
2,500
– – 0.01% 292
2026
Q1 		$47.4K Hold
2,500
– – 0.02% 256
2025
Q4 		$43.7K Hold
2,500
– – 0.01% 259
2025
Q3 		$51.6K Hold
2,500
– – 0.02% 250
2025
Q2 		$53.2K Hold
2,500
– – 0.02% 242
2025
Q1 		$48.2K Hold
2,500
– – 0.02% 241
2024
Q4 		$44.6K Hold
2,500
– – 0.02% 249
2024
Q3 		$54.7K Hold
2,500
– – 0.02% 237
2024
Q2 		$19.5K Hold
2,500
– – 0.01% 305
2024
Q1 		$10.3K Hold
2,500
– – ﹤0.01% 357
2023
Q4 		$11.3K Hold
2,500
– – ﹤0.01% 344
2023
Q3 		$4.65K Hold
2,500
– – ﹤0.01% 412
2023
Q2 		$5.22K Hold
2,500
– – ﹤0.01% 391
2023
Q1 		$4.38K Hold
2,500
– – ﹤0.01% 410
2022
Q4 		$10.6K Hold
2,500
– – 0.01% 319
2022
Q3 		$3K Hold
2,500
– – ﹤0.01% 431
2022
Q2 		$3K Hold
2,500
– – ﹤0.01% 412
2022
Q1 		$6K Buy
2,500
+1,500
+150% +$3.78K ﹤0.01% 365
2021
Q4 		$3K Buy
+1,000
New +$4.81K ﹤0.01% 393

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Adirondack Trust Company's SMMT Position: Q2 2026 in Review

Adirondack Trust Company held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 2,500 shares worth $36.4K. The position accounts for 0.01% of the portfolio, ranked #292.

Adirondack Trust Company first reported a position in SMMT in Q4 2021 and has held it in 19 quarters since. The position peaked at $54.7K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Adirondack Trust Company held 2,500 shares of Summit Therapeutics worth $36.4K as of Q2 2026.
  • Adirondack Trust Company left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up 0.01% of Adirondack Trust Company's portfolio in Q2 2026, its #292 holding.
  • Adirondack Trust Company first reported a position in Summit Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Adirondack Trust Company's Summit Therapeutics position peaked at $54.7K in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Adirondack Trust Company's 13F filing for Q2 2026, filed 16 Jul 2026.